Inventor
Scott D. Edmondson
Inventor
Clark, NJ, US
Overview
Patents· 45 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds42%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations38%
A61KPreparations for medical, dental or toiletry purposes16%
C07CAcyclic or carbocyclic compounds2%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
PatentTitleYear
10,239,863Factor XIa inhibitors201910,214,512Factor XIA inhibitors201910,123,995Factor XIa inhibitors201810,093,683Factor XIa inhibitors201810,081,617Factor XIa inhibitors201810,011,585Factor XIa inhibitors20189,975,874Factor XIa inhibitors20189,944,643Factor XIa inhibitors20189,868,727'Factor XIa inhibitors'20189,809,545'Factor XIa inhibitors'20179,783,530'Factor Xla inhibitors'20179,676,723'Factor XIa inhibitors'20179,663,527'Factor XIa inhibitors'20179,422,266'Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment'20169,186,354'Pyrrolidine derived β3 adrenergic receptor agonists'20159,018,224'Substituted cyclopropyl compounds useful as GPR119 agonists'20159,006,228'Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment'20158,957,062'Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment'20158,933,102'Pyrrolidine derived β3 adrenergic receptor agonists'20158,748,433'β3 adrenergic receptor agonists'20148,653,260'Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists'20148,618,144'Pyrrolidine-derived beta 3 adrenergic receptor agonists'20138,604,038'Pyrrolidine derived beta 3 adrenergic receptor agonists'20138,501,786'Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists'20138,440,668'Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes'20138,399,480'Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists'20138,354,403'Pyrrolidine derived beta 3 adrenergic receptor agonists'20138,247,415'Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists'20128,168,637'Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes'20128,017,624'Fused aminopiperidines as dipeptidyi peptidase-IV inhibitors for the treatment or prevention of diabetes'20117,977,339'Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators'20117,943,615'Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes'20117,884,104'Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes'20117,858,629'Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators'20107,795,265'Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators'20107,759,352'Substituted imidazole-4-carboxamides as cholecystokinin-1 receptor modulators'20107,718,667'Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes'20107,687,492'1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes'20107,456,204'Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes'20087,332,520'Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes'20087,208,498'Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes'20077,157,490'Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes'20077,125,873'Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes'20067,098,239'Dipeptidyl peptidase inhibitors for the treatment of diabetes'20066,699,871'Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes'2004Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2004–2008Patents assigned to MERCK & CO INC (7)· patent assignee history
2004–2012Based in New York, NY, US· patent location history
2010–2019Patents assigned to MERCK SHARP & DOHME (38)· patent assignee history
2010–2019Based in Clark, NJ, US· patent location history
2012–2018Patents assigned to EDMONDSON SCOTT D (14)· patent assignee history
2012–2015Patents assigned to CHANG LEHUA (9)· patent assignee history
2012–2015Patents assigned to KAR NAM FUNG (7)· patent assignee history
2018–2019Based in Concord, MA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MERCK SHARP & DOHME | 38 | 2010–2019 |
| EDMONDSON SCOTT Dself | 14 | 2012–2018 |
| CHANG LEHUA | 9 | 2012–2015 |
| KAR NAM FUNG | 7 | 2012–2015 |
| MERCK & CO INC | 7 | 2004–2008 |
Locations
| Location | Patents | Span |
|---|---|---|
| Clark, New Jersey, US | 35 | 2010–2019 |
| New York, New York, US | 8 | 2004–2012 |
| Concord, Massachusetts, US | 2 | 2018–2019 |